Frequently Asked Questions
The market is segmented based on , By Types (Acute Intermittent Porphyria (AIP), Hereditary Coproporphyria (HCP) and Others), Treatment (Medications, Caloric Deprivation, Dehydration and Others), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
.
The Global Acute Hepatic Porphyria Treatment Market size was valued at USD 3.72 USD Million in 2021.
The Global Acute Hepatic Porphyria Treatment Market is projected to grow at a CAGR of 5% during the forecast period of 2022 to 2029.
The major players operating in the market include Teva Pharmaceutical Industries Ltd, Apotex , Pfizer , H. Lundbeck A/S, Lilly, F. HoffmannLa Roche Ltd, Mylan N.V, Siemens Healthcare GmbH, ACON Laboratories , Danaher, ARKRAY , Abbott, Alnylam Pharmaceuticals , Boston Scientific Corporation, BioRad Laboratories , Recordati Rare Diseases .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
